Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis

G. M. Baltariu, Kurt Wyler, Hans Jürgen Gober, Carmen Lienert, Myriam Schluep, Ernst‐Wilhelm Radü, Gennaro De Libero, Ludwig Kappos, Petra W. Duda

European Journal of Neurology · 2005 · 15 citations · 38 references

Concepts

Abstract

Glatiramer acetate (GA) treatment for relapsing remitting multiple sclerosis (RRMS) leads to decreased GA-specific proliferative responses and a Th2 cytokine shift. To study a possible correlation between immunological and clinical responses to GA therapy, we prospectively followed RRMS patients clinically, by magnetic resonance imaging and by primary immunological assays. Fluctuation of GA-specific proliferative responses was significantly lower in treatment responders than in untreated patients, and GA-specific proliferative responses were increased during relapses. These associations suggest a possible causal relationship between immunological and clinical responses to GA therapy. Primary proliferation assays may thus be a useful marker for treatment response.

References

38